AFM-13 is under clinical development by Affimed and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AFM-13’s likelihood of approval (LoA) and phase transition for Peripheral T-Cell Lymphomas (PTCL) took place on 13 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
In addition, the same event on 13 Dec 2022 increased AFM-13’s Phase Transition Success Rate (PTSR) for Transformed Mycosis Fungoides.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AFM-13 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A.
Affimed, formerly Affimed Therapeutics, a subsidiary of Affimed NV, discovers and develops immunotherapies to treat hematologic cancers and solid tumors. The company is investigating AFM13, an innate cell engager, for the treatment of Peripheral T cell lymphoma, transformed mycosis fungoides, CD30-positive T cell lymphoma and Hodgkin’s lymphoma; AFM24, against solid tumors; AFM-26, targeting B-cell maturation antigen to treat multiple myeloma. It generates multi-specific antibodies to kill tumor cells and treat cancers through its ROCK platform technology. The company works in partnership with Amphivena Therapeutics Inc, Merck & Co Inc, Genentech Inc, AbCheck SRO and other companies to advance its pipeline. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany
Quick View AFM-13 LOA Data
|Highest Development Stage|